Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

1

-	-									
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

STATEMENT OF CI	HANGES IN BENEFICIAL	OWNERSHIP
-----------------	----------------------	------------------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			of Section 30(n) of the investment Company Act of 1940					
1. Name and Address of Reporting Person* Shanmugam Muthusamy			2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Snanmugan</u>	<u>1 Muthusan</u>	<u>ny</u>		X Director 10% Owner				
(Last) C/O ANI PHA	st) (First) (Middle) O ANI PHARMACEUTICALS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 04/18/2024	X Officer (give title below) Other (specify below) HEAD OF R&D, COO-NOVITIUM OPS				
210 MAIN STREET WEST			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable ne)				
(Street)				X Form filed by One Reporting Person				
BAUDETTE	MN	56623		Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication	•				
			Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of		d (A) or r. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock								68,652	D	
Common Stock	04/18/2024		S ⁽¹⁾		10,423	D	\$ 64.98 ⁽²⁾	799,429	Ι	Held by Esjay LLC ⁽³⁾
Common Stock	04/19/2024		S ⁽¹⁾		16,809	D	\$65.17 ⁽⁴⁾	782,620	Ι	Held by Esjay LLC ⁽³⁾
Common Stock								5,000	Ι	Held by SS Pharma LLC ⁽⁵⁾

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

2. The shares were sold in multiple trades at prices ranging from \$64.43 to \$65.89. The price reported above reflects the weighted average sales price.

3. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

4. The shares were sold in multiple trades at prices ranging from \$64.20 to \$65.79. The price reported above reflects the weighted average sales price.

5. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Remarks:

/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith 04/22/2024 W. Cook

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.